STOCK TITAN

Labcorp (LH) director acquires 897 shares as RSUs vest into stock

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Labcorp Holdings Inc. director Kirsten Marie Kliphouse reported acquiring 897 shares of common stock through the vesting and conversion of restricted stock units. The RSUs fully vested on February 11, 2026, and after the transaction she directly holds 3,160 Labcorp common shares and 773 restricted stock units.

Positive

  • None.

Negative

  • None.
Insider Kliphouse Kirsten Marie
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Unit 897 $0.00 --
Exercise Common Stock 897 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 773 shares (Direct); Common Stock — 3,160 shares (Direct)
Footnotes (1)
  1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. The Restricted Stock Units vested fully on February 11, 2026. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kliphouse Kirsten Marie

(Last) (First) (Middle)
531 SOUTH SPRING STREET

(Street)
BURLINGTON NC 27215

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/11/2026 M 897 A (1) 3,160 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 02/11/2026 M 897 (2) (2) Common Stock 897 $0 773(3) D
Explanation of Responses:
1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
2. The Restricted Stock Units vested fully on February 11, 2026.
3. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
/s/ Kathryn W. Kyle, Attorney-in-Fact for Kirsten M. Kliphouse 02/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Labcorp (LH) director Kirsten Kliphouse report?

Kirsten Marie Kliphouse reported the vesting and conversion of 897 restricted stock units into Labcorp common stock. This was recorded as an exercise or conversion of a derivative security on February 11, 2026, increasing her directly held common shares.

How many Labcorp (LH) shares does Kirsten Kliphouse hold after this Form 4?

After the reported transaction, Kirsten Marie Kliphouse directly holds 3,160 shares of Labcorp common stock. She also beneficially owns 773 restricted stock units, which represent rights to receive additional Labcorp shares in the future under the company’s equity program.

What does the 897 restricted stock unit conversion mean for Labcorp (LH)?

The 897 restricted stock units converted into 897 Labcorp common shares upon vesting. This reflects part of the director’s equity-based compensation. It represents an increase in her actual share ownership rather than an open-market purchase or sale of Labcorp stock.

Was the Labcorp (LH) insider transaction a stock purchase or sale?

The filing shows an exercise or conversion of derivative securities, not a market purchase or sale. 897 restricted stock units vested and converted into 897 Labcorp common shares at a stated price of $0.00 per share, reflecting equity compensation rather than a cash trade.

When did Kirsten Kliphouse’s restricted stock units in Labcorp (LH) vest?

The restricted stock units reported in the filing fully vested on February 11, 2026. On that date, 897 units converted into 897 shares of Labcorp common stock, and 773 restricted stock units remained beneficially owned by the reporting person after the transaction.